Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 627 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06538311RecruitingEarly Phase 1
TMS treatment for early Alzheimer's disease
This study tests whether a non-invasive brain stimulation treatment called TMS (transcranial magnetic stimulation) can help people with early Alzheimer's disease or related memory problems. It's a safe, gentle way to stimulate brain cells using magnetic pulses.
Boston, MassachusettsAges 40–99 - NCT06565143Recruiting
Brain stimulation for early Alzheimer's disease
This trial tests whether a gentle, non-invasive electrical brain stimulation method called tACS can help people in the early stages of Alzheimer's disease. You may be eligible if you have mild cognitive impairment or early dementia and have been on a common Alzheimer's medication for at least 3 months.
Hefei, AnhuiAges 50–85 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06582199Recruiting
Personalized Alzheimer's study using brain scans and spinal fluid
This study looks at how to better predict and understand Alzheimer's disease by using advanced brain scans and spinal fluid tests. It aims to find ways to identify people who stay healthy longer despite risk factors.
ParisAges 50–90 - NCT06582706RecruitingPhase 1/Phase 2
Vitamin B3 (niacin) for Alzheimer's disease
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Indianapolis, IndianaAges 60–85 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06585384RecruitingPhase 1
Safety of etanercept with contrast ultrasound for Alzheimer's
This study tests whether combining a drug called etanercept with repeated contrast ultrasound is safe for people with mild Alzheimer's. It aims to see if this approach can help slow the disease.
ParisAges 50–85 - NCT06595511Recruiting
Combined sound, light, and games for Alzheimer's
This study tests a new approach combining special audio-visual stimulation (at 40 Hz) with cognitive games to see if it can help people with Alzheimer's disease. It also includes a group of healthy older adults for comparison.
Istanbul, BeykozAges 60–86 - NCT07347574Recruiting
Early Alzheimer's detection study in Hong Kong communities
This study aims to find early signs of Alzheimer's in the community through blood tests and assessments. It's for people who can think clearly and agree to participate without major health issues.
Hong KongAges 60–75 - NCT06611878Recruiting
Music training for Alzheimer's patients at home
This trial tests whether intensive music training can help memory in people with Alzheimer's disease who live at home and are not musicians.
Buenos AiresAges 65 years+ - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06661564Recruiting
Testing tears for Alzheimer's disease diagnosis
This study looks at whether tears can help detect Alzheimer's disease. You will have your tears collected and tested for possible biomarkers.
Tours, FranceAges 18 years+ - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06669182Recruiting
Cerebellar TMS for Alzheimer's Disease
This trial uses a non-invasive brain stimulation technique (TMS) to target the cerebellum in people with Alzheimer's disease. It aims to see if this treatment can improve symptoms and cognitive function.
Xi'an, ShaanxiAges 50–85 - NCT06678100Recruiting
Swallowing study for adults with Alzheimer's
This study looks at swallowing problems in people with Alzheimer's disease compared to healthy older adults. If you have Alzheimer's, you'll have a swallowing test and your caregiver will answer questions about your daily life.
Nashville, TennesseeAges 60 years+ - NCT06688968Recruiting
Music, thinking, and memory in Parkinson's and Alzheimer's
This study looks at how music engagement affects thinking and memory in people with Parkinson's or Alzheimer's disease. It may help researchers understand how music can support brain health as we age.
Montpellier, HéraultAges 60 years+ - NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT06703541Recruiting
Alzheimer's disease research study with brain scans and spinal tap
This study at Duke University is looking for people aged 25 to 80 who may be at risk for Alzheimer's disease. It involves brain scans (MRI and PET) and a spinal tap to learn more about the disease and find better ways to detect and treat it early.
Durham, North CarolinaAges 25–80 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT04576793RecruitingPhase 2
Imaging brain inflammation in Alzheimer’s and related variants over time
This Phase 2 study uses repeated brain MRI scans to track “microglial activation,” which is a marker of brain immune/inflammation activity, in different Alzheimer’s-related conditions. It may help researchers understand how brain inflammation changes over time and differs between people with these clinical variants.
New York, New YorkAges 50 years+ - NCT07688460RecruitingPhase 4
Blood test to monitor Alzheimer's drug Lecanemab
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Yiwu, ZhejiangAges 50–90 - NCT06731049Recruiting
Walking training with and without dual tasks for Alzheimer's
This study compares treadmill walking to walking while doing a second task (like talking or carrying something) in people with Alzheimer's disease. It aims to see which training method improves mobility and safety better.
IstanbulAges 65–85 - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+ - NCT06741553Recruiting
Studying lecanemab for early Alzheimer's disease
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hangzhou, ZhejiangAges Up to 85 years
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 627 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.